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Abstract
Nephrogenic diabetes insipidus (NDI) is a rare disorder characterized by resis-
tance of the kidney to the action of antidiuretic hormone (ADH), resulting in
a decrease in the capacity of the kidney to concentrate the urine. NDI can be
inherited or acquired due to, for example, chronic lithium therapy. Current
treatment options are limited to attempts to lower urine output by a
low-solute diet and the use of diuretics or anti-inflammatory drugs. These
measures are only partially effective. Recent reports suggested that sildenafil,
metformin, and simvastatin might improve ADH-independent urine concen-
tration. If confirmed, this would provide interesting additional therapeutic
options for patients with NDI. We, therefore, tested the effect of these drugs
on ADH-independent urine concentrating capacity in healthy volunteers. We
included 36 healthy volunteers who received sildenafil 20 mg thrice daily, met-
formin 500 mg thrice daily or simvastatin 40 mg once daily during 1 week.
At baseline and at the end of treatment, a water loading test was performed.
No significant increase in lowest urine osmolality was seen after the use of
metformin or sildenafil (P = 0.66 and P = 0.09 respectively). Lowest urine
osmolality increased modestly but significantly after the use of simvastatin
(70 mOsm/kg to 85 mOsm/kg, P = 0.05). Our data suggest that only simvas-
tatin has an effect on urine osmolality in healthy volunteers. Validation stud-
ies are needed and, most importantly, these drugs should be tested in patients
with NDI.
Introduction
Nephrogenic diabetes insipidus (NDI) is a rare disorder
characterized by resistance of the kidney collecting duct
to the action of antidiuretic hormone (ADH), resulting in
a decrease in the capacity of the kidney to concentrate
urine. Water reabsorption in the collecting duct is initi-
ated by ADH that binds to its receptor (type 2 vaso-
pressin receptor, V2R) in the collecting duct principal
cells (Fig. 1). Activation of the V2R activates an intracel-
lular signaling cascade in which stimulation of adenylyl
cyclase (AC) leads to the production of cyclic adenosine
monophosphate (cAMP), which in turn stimulates the
insertion of aquaporin-2 water channels (AQP2) into the
apical membrane through which water can enter the cell.
Hereditary NDI is caused by mutations in the AVPR2
gene (encoding for the V2R) in the vast majority of
patients, leading to X-linked NDI. Alternatively, muta-
tions in the AQP2 gene (encoding aquaporin-2) can cause
either autosomal-dominant or recessive NDI, or it can
occur in the context of hereditary tubulointerstitial kidney
diseases. The most common cause of acquired NDI is
chronic lithium therapy. The inability to concentrate
urine results in high urine volumes, which can be as high
as 15 L per day in patients with hereditary NDI. This can
lead to several secondary problems, such as hypernatremia
and rapid dehydration when water intake is restricted. In
addition, chronic vesicoureteral reflux leading to chronic
kidney injury can occur due to chronically high bladder
volumes. Current treatment consists of countering the
polyuria by drinking large amounts of water and attempts
to lower urine output by a low-salt and low-protein diet,
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the use of nonsteroidal anti-inflammatory drugs and the
use of diuretics that increase proximal sodium and water
reabsorption and/or prevent lithium influx into principal
cells (Crawford et al. 1960; Forrest et al. 1974; Korteno-
even et al. 2009; Bockenhauer and Bichet 2015). These
measures, however, are only partly able to correct the
polyuria. Therefore, NDI is a chronic disease seriously
affecting the quality of life.
Recent reports have suggested novel therapeutic
options by repurposing already available and FDA
approved drugs that could, theoretically, be more effec-
tive than the current standard of care (Sands and Klein
2016). The rationale for using these drugs in the context
of NDI is based on the fact that they would be able to
beneficially target the intracellular signaling cascade
downstream to the V2R receptor in the collecting tubule
cell and thereby potentially rescue, at least in part, urine
concentrating ability (Fig. 1). The first drug for which a
potential positive effect on urine concentration was sug-
gested is sildenafil, currently registered for use in erectile
dysfunction and pulmonary hypertension. Sildenafil
increases cyclic guanosine monophosphate (cGMP)
which, like cAMP, is thought to be able to induce phos-
phorylation of AQP2 and thereby promote insertion of
AQP2 water channels into the apical membrane (Fig. 1).
Sildenafil indeed increased the apical accumulation of
AQP2 in rats with central diabetes insipidus (Bouley
et al. 2005; Sanches et al. 2012). Assadi and Sharbaf
(2015) described a child with a mutation in V2R who
showed a lower urine volume and higher urine osmolal-
ity after 10 days treatment with sildenafil compared to
conventional treatment with hydrochlorothiazide, amilor-
ide, and indomethacin. The second potential drug is
metformin, currently registered for use in diabetes melli-
tus. Metformin activates adenosine monophosphate
kinase (AMPK), which increases phosphorylation and
accumulation of AQP2 (Fig. 1). Metformin resulted in
an increase in urine osmolality in V2R knockout mice
and tolvaptan-treated rats (Efe et al. 2016; Klein et al.
2016). The third potential drug is simvastatin, a choles-
terol-lowering drug of the HMG-CoA-reductase inhibitor
class of drugs. With respect to NDI, simvastatin is
thought to enhance the expression of AQP2 through
down regulation of Rho GTPases and the inhibition of
AQP2 endocytosis (Fig. 1) (Li et al. 2011). In line with
this finding, it was shown that hypercholesterolemic
patients upon initiation of simvastatin show an increase
in urinary AQP2 and an increase in urine osmolality
(Procino et al. 2016).
These three drugs are thus hypothesized to have an
ADH-independent effect on AQP2 and water transport in
the collecting duct, where statins are mainly thought to
promote AQP2 trafficking to the membrane and sildenafil
and metformin would induce phosphorylation of AQP2.
These drugs could thereby serve as new treatment options
in patients with NDI, particularly by bypassing the defec-
tive V2R receptor signaling in patients with AVPR2 muta-
tions. In this study, we performed physiological
experiments determining whether these drugs affect
ADH-independent urine concentration in healthy man,
which would strengthen their therapeutic potential in
patients with NDI.
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Figure 1. Overview of potential therapeutic targeting of the intracellular mechanisms involved in transcellular water reabsorption in the
collecting duct. Upon vasopressin (AVP) binding to its receptor (V2R) at the basolateral side of the principal collecting duct cells, an intracellular
signaling cascade is activated that ultimately results in phosphorylation and subsequent insertion of aquaporin-2 water channels (AQP2) in the
apical membrane. Sildenafil is hypothesized to target this cascade by increasing cyclic guanosine monophosphate (cGMP), metformin by
increasing adenosine monophosphate-activated protein kinase (AMPK) and simvastatin through inhibiting the recycling of AQP2 and thereby a
net increase in AQP2 channels inserted in the membrane. UT-A1, urea transporter A1; AC, adenylyl cyclase; V2R, vasopressin receptor type 2;
AVP, arginine vasopressin.
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Methods
Study population
We performed a study in 36 healthy volunteers, aged
>18 year and not using any medication. After informed
consent, each healthy volunteer received either sildenafil
(20 mg thrice daily), metformin (500 mg thrice daily) or
simvastatin (40 mg once daily) during 1 week. In total,
12 healthy volunteers per study medication were included.
A water loading test was performed to evaluate ADH-
independent urine concentration/dilution. This study had
a cross-over design, that is, each patient was studied after
1 week on and off therapy with at random selection of
the order of the study periods.
The tests were performed in the Radboud university
medical center by a group of trained nurses. This study
was approved by the medical ethics committee of the
Radboud university medical center Nijmegen, and all par-
ticipants provided written informed consent.
Water loading test
In the 24 h preceding the test, the subjects were not
allowed to smoke cigarettes or drink alcohol or coffee.
On the morning of the test, subjects were allowed to have
a small breakfast without coffee or tea. They were
instructed to drink two glasses of water before going to
bed and to drink an extra glass of water at breakfast.
The healthy volunteers then visited the clinic at 8:00 h
in the morning. At that time (T = 0), subjects were
weighed, blood pressure was measured and a urine sam-
ple was taken. Next they were requested to lie down for
one hour. At T = 60 (min), a urine and blood sample
were taken and the subject was instructed to drink
20 mL/kg of body weight in 15 min. Thereafter, every
hour, urine samples were collected during 4 h. At
T = 300, an additional blood sample was withdrawn and
body weight and blood pressure were measured again.
During the test, participants were not allowed to eat, to
drink coffee or tea, and they were not allowed to smoke
cigarettes. Except for going to the toilet, the subjects were
seated and not allowed to walk around.
Statistics
Baseline characteristics are reported as median values with
interquartile ranges. Medians between the baseline test
and the test after medication were compared, using a
Wilcoxon matched pairs test. Spearman correlation coeffi-
cients were used to perform univariate analyses. Statistical
significance was defined as a two-sided P -value of <0.05.
Statistical analyses were performed, using SPSS.
Power calculation
We considered an increase in lowest osmolality of more
than 20 mOsm/kg clinically relevant. A power calculation
with a two-sided paired T test with a power of 0.80, an
alpha of 0.05 results in a number of 12 subjects per drug.
Results
Test results of the subjects on sildenafil are shown in
Table 1 and Figure 2. Eight out of twelve subjects were
male. Median age was 27 years (IQR 22–34). Urine
Table 1. Test characteristics in the sildenafil group.
Without sildenafil With sildenafil P value
Body weight (kg) – start 73 (63–90) 73 (64–89) 0.18
Body weight (kg) – end 72 (63–90) 72 (64–92) 0.05
Systolic BP – start 123 (120–134) 122 (112–132) 0.05
Systolic BP – end 124 (115–129) 128 (111–132) 0.42
Diastolic BP – start 73 (64–77) 66 (61–73) 0.37
Diastolic BP – end 70 (66–80) 72 (59–76) 0.19
Pulse – start 75 (61–91) 82 (70–91) 0.21
Pulse – end 61 (53–66) 62 (57–70) 0.25
Serum creatinine – start (lmol/L) 79 (63–89) 73 (68–88) 0.17
Urine osmol baseline (mOsm/kg) 441 (262–618) 226 (105–540) 0.18
Lowest urine osmol (mOsm/kg) 70 (61–83) 76 (70–89) 0.09
Sodium excretion (mmol in 300 min) 44 (36–52) 55 (50–64) 0.06
Potassium excretion (mmol in 300 min) 19 (15–25) 25 (21–32) 0.02
Urea excretion (mmol in 300 min) 95 (74–125) 100 (90–125) 0.43
Median values with IQR.
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osmolality at start of the water loading test was lower on
the test day after sildenafil compared to the test day with-
out sildenafil, but this difference was not significant. Low-
est urine osmolality was not significantly higher after the
use of sildenafil (+6 mOsm/kg, +9%, P = 0.09). Frequent
side effects were noted during the treatment period. Six
subjects experienced headache, four subjects blushing, one
subject diarrhea, one subject palpitations, one subject
dizziness, and four subjects did not experience side
effects.
Test results of the subjects on metformin are shown in
Table 2 and Figure 3. Five out of twelve subjects were
male. Median age was 20 years (IQR 19–25). Urine osmo-
lality at start of the water loading test was lower on the
test day after metformin compared to the test day with-
out metformin, but this difference was not significant.
Lowest urine osmolality was not different after the use of
metformin (7 mOsm/kg, 10%, P = 0.66). Two sub-
jects did not experience any side effect, five subjects had
diarrhea, and eight subjects experienced nausea when
using metformin.
Test results of the subjects on simvastatin are shown in
Table 3 and Figure 4. Three out of twelve subjects were
male. Median age was 23 years (IQR 20–26). Urine osmo-
lality at start of the water loading test was significantly
lower on the test day after simvastatin compared to the
test day without simvastatin. Despite this, lowest urine
osmolality was significantly higher after the use of simvas-
tatin (+15 mOsm/kg, +21%, P = 0.05). One subject expe-
rienced abdominal pain and one subject experienced
headache during treatment with simvastatin.
As the urine osmolality at start of the water loading
tests differed between “baseline” and after the week on
study drugs in a significant number of subjects, we fur-
ther studied the relation between the urine osmolality at
start and the lowest urine osmolality. Overall, no correla-
tion was seen between urine osmolality at start and at the
end of the water loading tests (Fig. 5, Spearman’s
rho = 0.02, P = 0.86).
Figure 2. Effect of sildenafil on urine osmolality after a water
loading test in healthy subjects. The lowest urine osmolality after
water loading in healthy subjects is depicted either with or without
prior treatment with sildenafil (20 mg thrice daily) during 1 week.
Table 2. Test characteristics in the metformin group.
Without metformin With metformin P value
Body weight (kg) – start 69 (58–78) 69 (59–77) 0.27
Body weight (kg) – end 68 (58–77) 68 (58–77) 0.08
Systolic BP – start 117 (111–128) 115 (110–124) 0.39
Systolic BP – end 126 (111–140) 116 (107–128) 0.12
Diastolic BP – start 66 (60–72) 67 (61–70) 0.61
Diastolic BP – end 63 (58–74) 70 (60–72) 0.92
Pulse – start 77 (69–89) 71 (61–79) 0.01
Pulse – end 63 (60–72) 61 (59–66) 0.24
Serum creatinine – start (lmol/L) 73 (62–78) 73 (68–81) 0.13
Urine osmol baseline (mOsm/kg) 368 (153–651) 188 (87–651) 0.75
Lowest urine osmol (mOsm/kg) 70 (56–82) 63 (59–78) 0.66
Sodium excretion (mmol in 300 min) 43 (36–49) 35 (31–49) 0.21
Potassium excretion (mmol in 300 min) 23 (17–27) 17 (16–23) 0.24
Urea excretion (mmol in 300 min) 91 (79–102) 75 (66–97) 0.12
Median values with IQR.
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Discussion
In this study, we tested whether sildenafil, simvastatin or
metformin stimulated ADH-independent urine concentra-
tion in healthy volunteers. Based on the pathophysiological
mechanisms and studies in animal models it was expected
that these drugs could increase ADH-independent water
reabsorption.
We observed a significant, although limited, increase in
lowest urine osmolality after simvastatin. No significant
differences were observed with sildenafil or metformin.
To appreciate the clinical relevance of the 21% higher
urine osmolality with simvastatin, the effects should be
compared with that of standard diuretic therapy.
Hydrochlorothiazide reduces water requirement by 24–
47% (Crawford et al. 1960; Forrest et al. 1974). Although
relatively limited in extent, the use of simvastatin could
be beneficial to patients with NDI by reducing urine pro-
duction by approximately 20%. Obviously, our data need
to be confirmed and validated in patients with NDI.
The lack of an effect of sildenafil and metformin seems
in contrast to earlier reports. Of note, the effects of the
three drugs have been mainly tested and demonstrated in
animal models.
Effects of metformin on urine concentration were only
studied in rodent models. Treatment with 800 mg/kg/day
metformin for 4 days increased collecting duct expression
of AQP2, increased urine osmolality by 80% in tolvaptan-
treated rats and increased urinary osmolality by 31% in
healthy rats (although this increase was not significant
with a P -value of 0.08) (Efe et al. 2016). Already a single
dose of 600 mg/kg metformin increased urine osmolality
by 180–200% in V2R knock-out mice (Efe et al. 2016;
Klein et al. 2016).
A 3-week treatment with sildenafil did not affect urine
osmolality in healthy rats (Sanches et al. 2012). In con-
trast, a single dose of 4 mg/kg sildenafil increased kidney
tubular AQP2 expression in Brattleboro rats, a model of
Figure 3. Effect of metformin on urine osmolality after a water
loading test in healthy subjects. The lowest urine osmolality after
water loading in healthy subjects is depicted either with or without
prior treatment with metformin (500 mg thrice daily) during
1 week.
Table 3. Test characteristics in the simvastatin group.
Without simvastatin With simvastatin P value
Body weight (kg) – start 67 (59–75) 68 (59–74) 0.94
Body weight (kg) – end 67 (58–76) 67 (58–73) 0.50
Systolic BP – start 122 (113–132) 121 (114–133) 0.62
Systolic BP – end 118 (111–124) 120 (115–124) 0.70
Diastolic BP – start 70 (66–74) 71 (65–79) 0.97
Diastolic BP – end 66 (61–74) 69 (61–76) 0.81
Pulse – start 78 (75–90) 81 (62–90) 0.27
Pulse – end 61 (55–77) 61 (53–77) 0.67
Serum creatinine – start (lmol/L) 79 (68–92) 71 (61–87) 0.02
Urine osmol baseline (mOsm/kg) 760 (353–937) 388 (187–388) 0.02
Lowest urine osmol (mOsm/kg) 70 (61–89) 85 (65–96) 0.05
Sodium excretion (mmol in 300 min) 44 (36–51) 54 (43–61) 0.11
Potassium excretion (mmol in 300 min) 20 (12–32) 26 (13–35) 0.45
Urea excretion (mmol in 300 min) 90 (74–100) 101 (77–110) 0.33
Median values with IQR.
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central diabetes insipidus (Bouley et al. 2005). In support
of its efficacy, 200 mg sildenafil per kg food administered
for 3 weeks to rats with lithium-induced NDI, increased
urine osmolality by 37% (Sanches et al. 2012).
Brattleboro rats were also used to evaluate the effects
of simvastatin on kidney water handling. A single dose of
simvastatin increased urine osmolality by ~70% (Li et al.
2011). A single injection of fluvastatin resulted in a mod-
est decrease in urine production in V2R-mutant mice
(Procino et al. 2014). If these same mice were pretreated
with secretin, which activates AQP2 gene transcription
and thereby increases intracellular AQP2 stores, fluvas-
tatin resulted in a ~90% reduction in urine output
(Procino et al. 2014).
Overall, the number of studies in animal models is lim-
ited, and only one study evaluated the effect of prolonged
treatment. Another important observation is that the vast
majority of studies were performed in animal models for
diabetes insipidus, whereas the studies in healthy animals
did not show a significant effect. Differences in drug dos-
ing could also be relevant. Although we cannot exclude
that higher dosages of the drugs could be more effective,
for metformin and sildenafil the use of a higher dose does
not seem feasible in view of the many known side effects,
as also reported by our volunteers. Obviously, it is difficult
to compare these studies in animal models with our water
loading test in healthy humans.
The potential role of sildenafil and simvastatin in the
treatment of NDI was supported by few studies in
humans and, thus, the evidence base is very limited.
Sildenafil in a dose of 2 mg/kg/day for 10 days was used
in a child with NDI due to a mutation in the V2R
(Assadi and Sharbaf 2015). Conventional therapy with
hydrochlorothiazide, amiloride and indomethacin were
continued. Treatment with sildenafil was associated with
an increased urine osmolality (from 104 to 215 mosmol/
kg) and a parallel reduction in urine output (from 1764
to 950 mL). Data on prolonged treatment and follow up
are lacking. There is evidence that simvastatin could posi-
tively affect urine concentration capacity in humans. Pro-
cino et al. (2016) started simvastatin 20 mg/day in
patients with hypercholesterolemia. Within 1 week, urine
AQP2 and urine osmolality increased by 36%, an effect
that was maintained for 12 weeks. Urine production con-
comitantly decreased, although to a much lesser degree.
Although the authors suggest that their data provide evi-
dence that simvastatin has pleiotropic effects and influ-
ences water reabsorption, the data can be interpreted
differently. No information is given on food and water
intake, both important parameters of urine output.
Reduced water intake will simultaneously increase urine
osmolality and urine AQP2 excretion. The authors do not
provide serum sodium levels, which would allow differen-
tiating between ADH-dependent or independent increased
water reabsorption. Moreover, as a control group, the
authors included patients who had been treated with sim-
vastatin for 1 year. Diuresis in these patients was not dif-
ferent than diuresis of treatment-naive patients.
Figure 4. Effect of simvastatin on urine osmolality after a water
loading test in healthy subjects. The lowest urine osmolality after
water loading in healthy subjects is depicted either with or without
prior treatment with simvastatin (40 mg once daily) during 1 week.
Figure 5. Correlation of baseline urine osmolality and lowest urine
osmolality during the water loading test. Depicted is the lowest
urine osmolality measured during the water loading test as a
function of the urine osmolality measured at the start of the water
loading test. Spearman’s rho = 0.02, P = 0.86.
2018 | Vol. 6 | Iss. 7 | e13665
Page 6
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Urine Concentration in Healthy Volunteers A. P. Bech et al.
Despite the overall lack of an effect with metformin
and sildenafil in our study, we suggest that testing a com-
bination of drugs such as simvastatin and sildenafil could
be considered. As statins mainly promote AQP2 traffick-
ing to the membrane and sildenafil or metformin induce
phosphorylation of AQP2, using a combination of both a
statin with sildenafil or metformin could theoretically
have a synergistic effect. Procino supports this hypothesis
by showing that fluvastatin alone does not result in a
clinically significant decrease in urine output in V2R-
mutant mice but when it was combined with secretin,
which increases intracellular stores of AQP2, it induced a
significant decrease in urine output (Procino et al. 2014).
The most important limitations of our study are the trial
design which is open, not blinded, and the inclusion of
healthy subjects as opposed to NDI patients. The lack of an
effect in healthy volunteers does not rule out a potential
effect in patients with NDI as acute water loading in healthy
subject can possibly result in different ADH-related changes
than in patients with NDI who have a chronically down-
regulated ADH system. Another limitation is that we did
not control dietary intake of our subjects. Large differences
in osmolar intake can affect minimal urine osmolality
(Kleeman et al. 1956). Although we observed slight differ-
ences in sodium and urea excretion between the two tests
within individual subjects, these differences were not statis-
tically significant. More importantly, if we take these differ-
ences into account, the effects of sildenafil and simvastatin
on urine osmolality would be even less evident. This sup-
ports our conclusion that the drugs are not effective in
affecting urine osmolality in healthy subjects.
In conclusion, although insight in the pathophysiologi-
cal mechanisms provides arguments that metformin,
sildenafil, and simvastatin could increase ADH-indepen-
dent water reabsorption, experimental evidence is very
limited. Our data suggest that simvastatin might have an
effect in healthy volunteers. Validation studies are needed
and, most importantly, these drugs should be tested alone
and in combination in patients with NDI.
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